A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...

Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed an investigational therapy for ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Amgen, AstraZeneca focus on asthmatic punk rocker to show how Tezspire can unleash lust for life In the WAYPOINT study, ...

Tocilizumab treatments in patients with noninfectious uveitis demonstrated high rates of success at 1 year follow ups.

Results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in overweight patients with cardiovascular disease.

The Quadruple Aim—a framework originally rooted in improving patient experience, enhancing population health, and achieving ...

Related: Ozempic (Semaglutide) - Subcutaneous When a drug is on the FDA shortage list, compounding pharmacies can legally mix ...

Aurinia has announced a 45% workforce reduction to bolster sales of the lupus drug Lupkynis and advance the development of ...

Johnson & Johnson announced the submission of regulatory applications to the U.S. FDA and European Medicines Agency seeking approval of a ...